Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-03-08
2008-10-14
McKane, Joseph (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S340000, C514S314000, C514S307000, C514S378000, C514S406000, C514S397000, C514S444000, C514S461000, C514S422000, C514S259310
Reexamination Certificate
active
07435750
ABSTRACT:
The present invention is directed to substituted 3-aryl-5-aryl-[1,2,4]-oxadiazoles and analogs thereof, represented by the Formula I:wherein Ar1, Ar3, A, B and D are defined herein. The present invention also relates to the discovery that compounds having Formula I are activators of caspases and inducers of apoptosis. Therefore, the activators of caspases and inducers of apoptosis of this invention may be used to induce cell death in a variety of clinical conditions in which uncontrolled growth and spread of abnormal cells occurs.
REFERENCES:
patent: 3192103 (1965-06-01), Sousa et al.
patent: 3211742 (1965-10-01), Lenaers
patent: 3325446 (1967-06-01), Chang et al.
patent: 3772441 (1973-11-01), Lombardino
patent: 3879404 (1975-04-01), Baldwin et al.
patent: 3910940 (1975-10-01), Narayanan et al.
patent: 4022901 (1977-05-01), Narayanan et al.
patent: 4791124 (1988-12-01), Lutomski et al.
patent: 5134142 (1992-07-01), Matsuo et al.
patent: 6121260 (2000-09-01), Thurkauf et al.
patent: 6277873 (2001-08-01), Yu et al.
patent: 6620828 (2003-09-01), Chu et al.
patent: 2005/0004005 (2005-01-01), Kasibhatla et al.
patent: WO 96/20721 (1996-07-01), None
U.S. Appl. No. 11/593,030, filed Nov. 2006, Cai et al.
Cancer and apoptosis, Wikipedia, encyclopedia on-line vrsion.
STN search result on US Patent 6,620,828.
Batteux, F., et al., “Gene Therapy of Experimental Autoimmune Thyroiditis by In Vivo Administration of Plasmid DNA Coding for Fas Ligand,”J. Immunol. 162:603-608, The American Association of Immunologists (1999).
Boirivant, M., et al., “Lamina Propria T Cells in Crohn's Disease and Other Gastrointestinal Inflammation Show Defective CD2 Pathway-Induced Apoptosis,”Gastroenterology 116:557-565, The American Gastroenterological Association (1999).
Chinnaiyan, A.M., et al., “The Inhibition of pro-apoptotic ICE-like proteases enhances HIV replication,”Nat. Med. 3:333-337, Nature Publishing Co. (1997).
Coven, T.R., et al., “PUVA-induced lymphocyte apoptosis: Mechanism of action in psoriasis,”Photodermatol. Photoimmunol. Photomed. 15:22-27, Munksgaard (1999).
Ellis, R.E., et al., “Mechanisms and Functions of Cell Death,”Ann. Rev. Cell Biol. 7:663-698, Annual Reviews, Inc. (1991).
Friesen, C., et al., “Involvement of the CD95 (APO-1/FAS) receptor/ligand system in drug-induced apoptosis in leukemia cells,”Nat. Med. 2:574-577, Nature Publishing Co. (1996).
Greenwald, R.B., “Drug Delivery Systems Employing 1,4- or 1,6-Elimination: Poly(ethylene glycol) Prodrugs of Amine-Containing Compounds,”J. Med. Chem. 42:3657-3667, American Chemical Society (1999).
Heenen, M., et al., “Methotrexate induces apoptotic cell death in human keratinocytes,”Arch. Dermatol. Res. 290:240-245, Springer-Verlag (1998).
Infante, A.J., et al., “The clinical spectrum in a large kindred with autoimmune lymphoproliferative syndrome caused by a Fas mutation that impairs lymphocyte apoptosis,”J. Pediatr. 133:629-633, Mosby, Inc. (1998).
Leu, Y.-L., et al., “Design and Synthesis of Water-Soluble Glucuronide Derivatives of Camptothecin for Cancer Prodrug Monotherapy and Antibody-Directed Enzyme Prodrug Therapy (ADEPT),”J. Med. Chem. 42:3623-3628, American Chemical Society (1999).
López-Hoyos, M., et al., “Regulation of B cell apoptosis by Bcl-2 and Bcl-xL and its role in the development of autoimmune diseases (Review),”Int. J. Mol. Med. 1:475-483, D.A. Spandidos (1998).
Los, M., et al., “Cross-Resistance of CD95- and Drug-Induced Apoptosis as a Consequence of Deficient Activation of Caspases (ICE/Ced-3 Proteases),”Blood 90:3118-3129, W.B. Saunders Co. (1997).
O'Reilly, L.A. and Strasser, A., “Apoptosis and autoimmune disease,”Inflamm. Res. 48:5-21, Birkhäuser Verlag (1999).
Ohsako, S. and Elkon, K.B., “Apoptosis in the effector phase of autoimmune diabetes, multiple sclerosis and thyroiditis,”Cell Death Differ. 6:13-21, Stockton Press (1999).
Orrenius, S., “Apoptosis: molecular mechanisms and implications for human disease,”J. Internal Med. 237:529-536, Blackwell Science Ltd. (1995).
Ozawa, M., et al., “312-nanometer Ultraviolet B Light (Narrow-Band UVB) Induces Apoptosis of T Cells within Psoriatic Lesions,”J. Exp. Med. 189:711-718, The Rockefeller University Press (1999).
Savill, J., “Apoptosis in resolution of inflammation,”J. Leukoc. Biol. 61:375-380, The Society for Leukocyte Biology (1997).
Schmitt, E., et al., “The Bcl-xL and BAX-α control points: modulation of apoptosis induced by cancer chemotherapy and relation to TPCK-sensitive protease and caspase activation,”Biochem. Cell Biol. 75:301-314, National Research Council of Canada (1997).
Tai, D.-I., et al., “Activation of Nuclear Factor κB in Hepatits C Virus Infection: Implications for Pathogenesis and Hepatocarcinogenesis,”Hepatology 3:656-664, W.B. Saunders Co. (Mar. 2000).
Thornberry, N.A., “The caspase family of cysteine proteases,”Brit. Med. Bull. 53:478-490, Oxford University Press (1997).
Thornberry, N.A., “Caspases: key mediators of apoptosis,”Chem. Biol. 5:R97-R103, Current Biology Ltd. (1998).
Vaishnaw, A.K., et al., “The molecular basis for apoptotic defects in patients with CD95 (Fas/Apo-1) mutations,”J. Clin. Invest. 103:355-363, The American Society for Clinical Investigation (1999).
Wakisaka, S., et al., “Modulation by proinflammatory cytokines of Fas/Fas ligand-mediated apoptotic cell death of synovial cells in patients with rheumatoid arthritis (RA),”Clin. Exp. Immunol. 114119-128, Blackwell Science (1998).
Wyllie, A.H., et al., “Cell Death: The Significance of Apoptosis,”Int. Rev. Cyt. 68:251-306, Academic Press, Inc. (1980).
Wyllie, A.H., “Cell death: a new classification separating apoptosis from necrosis,” inCell death in biology and pathology, Bowen and Lockshin, eds., Chapman and Hall, London, England, pp. 9-34 (1981).
Zhou, T., et al., “Bisindolylmaleimide VIII facilitates Fas-mediated apoptosis and inhibits T cell-mediated autoimmune diseases,”Nat. Med. 5:42-48, Nature Publishing Co. (1999).
International Search Report for International Patent Application PCT/US02/17892, issued Mar. 26, 2003.
Cai Sui Xiong
Drewe John A.
Kasibhatla Shailaja
Kuemmerle Jared Daniel
Ollis Kristin P.
Chu Yong
Cytovia, Inc.
McKane Joseph
Sterne Kessler Goldstein & Fox P.L.L.C.
LandOfFree
Method of using substituted... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of using substituted..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of using substituted... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3996971